(RED) today announced the launch of The Lazarus Effect Campaign, a multi-platform campaign across TV, online and print, including an HBO documentary airing on May 24, that will help raise awareness of the transformative effect of antiretroviral medicine for those living with HIV in Africa. Launching April 29 on HBO, the awareness campaign will roll out across various TV and online networks in the coming weeks. The campaign equates the relative value of 40 cents by comparing trivial items worth 40 cents e.g. a stick of gum, a smear of lipstick — to the value of one day\'s worth of life transforming antiretroviral medication./nTo view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/red/43843/
Following FDA approval of the AspireSR® generator for the VNS Therapy® system in June 2015, more than a thousand patients with drug-resistant epilepsy across the United States have received this new treatment option. Many of these patients are experiencing benefits which have positively impacted their lives – and are sharing their stories during Epilepsy Awareness Month with the hope of encouraging others to seek new treatments for drug-resistant epilepsy. Numerous hospitals nationwide have begun providing the AspireSR device to patients with drug-resistant epilepsy – a condition that affects as many as one-third of people with epilepsy, causing them to have seizures in spite of treatment with antiepileptic medications.
The VNS Therapy system is a minimally invasive option in which a medical device is placed under the skin in the upper chest area during an outpatient procedure. The device sends mild electrical pulses through the vagus nerve to areas of the brain known to be associated with seizures. The new AspireSR generator takes the VNS Therapy technology a step further – detecting relative heart-rate increases that are often associated with seizures in people with epilepsy and providing responsive stimulation in an attempt to stop and shorten seizures and improve recovery.
To view the multimedia release go to:
http://www.multivu.com/players/English/7651751-livanova-aspiresr-treatment/
In recognition of Pain Awareness Month (PAM), the Let’s Talk Pain Coalition today launched the Pain Medication Safety Series, an online video series featuring candid dialogues between health care professionals, people with pain and their caaregivers about the safe and appropriate use of pain therapies. A complete listing of episodes with descriptions is available at www.letstalkpain.com/painmedsafety.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/letstalkpain/45730/
Hospira, Inc. (NYSE: HSP), a global specialty pharmaceutical and medication delivery company, today launched a new online U.S. product catalog, available at Hospira.com/catalog. Developed with input from customers, the new website allows healthcare facilities and other medical care providers to search Hospira's more than 1,200 products in a variety of ways – alphabetically, by product name, list number, or therapeutic class.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/hospira/48828/
The American Pain Foundation (APF) announced today the launch of new information and resources on pain medication safety for acetaminophen and nonsteroidal anti-inflammatory drugs (NSAIDs) as a part of its PainSAFE™ educational initiative. The new information will be launched with a national public service announcement (PSA) emphasizing the safe use of pain treatment options, particularly medications containing NSAIDs (aspirin, ibuprofen, naproxen) and acetaminophen (Tylenol, APAP). APF is the nation’s largest consumer advocacy organization dedicated to people with pain.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/painfoundation/49865/
CareFusion today launched the Pyxis® Enterprise System (ES) platform, a new generation of its industry-leading automated dispensing systems that will enable hospital customers to simplify and standardize the medication management process, both within a single facility and across an entire health system.
The new CareFusion Pyxis hardware and software brings key benefits to pharmacy, nursing and information technology (IT) departments.
To view Multimedia News Release, go to http://www.multivu.com/mnr/53365-carefusion-unveils-pyxis-automated-medication-dispensing-system
Today Safe Kids Worldwide released a new research report that found while the death rate among children from poisoning has been cut in half since the late 1970s, the percentage of all child poisoning deaths due to medications has nearly doubled, from 36 percent to 64 percent.
Safe Storage, Safe Dosing, Safe Kids: A Report to the Nation on Safe Medication examines trends in morbidity and mortality of medication poisoning among children ages 14 and under. The report underscores the challenge of medication-related poisoning among children and offers solutions that will reverse the trends. Safe Kids also proposes specific roles that parents and other caregivers, industry, governments, and the medical community can play in improving medication safety through safe storage and safe dosing.
To view Multimedia News Release, go to http://www.multivu.com/mnr/55155-safe-kids-worldwide-medication-safety-campaign-research-report
Vioxx Settlement
This is an important announcement for consumers about the prescription drug Vioxx. Vioxx was a drug commonly used to treat pain and inflammation in adults with arthritis.
A settlement was reached with the manufacturer of Vioxx and will provide refunds to anyone who paid for the medication. Consumers are eligible to get $50 or more. Personal injury claims related to this drug are not included in this settlement.
The deadline to file a claim is approaching – claims must be filed by May 6, 2014.
Details are available at http://www.VioxxSettlement.com or by calling 1-866-439-6932.
A recent survey conducted by Harris Poll on behalf of the newly-formed Coalition to Prevent Attention-Deficit/Hyperactivity Disorder (ADHD) Medication Misuse (CPAMM) finds that college students’ perceptions and attitudes towards the misuse, abuse and diversion of ADHD prescription stimulants are complex. The findings paint a portrait of students who recognize the risks of misuse, but understand why some students may choose to misuse, given the academic pressures in today’s college environment. CPAMM intends to use the findings to inform and develop educational campaigns to help prevent nonmedical use of ADHD prescription stimulants. The survey was conducted online between May 15 and June 11, 2014 among 2,056 US college students (full-time, 91%, part-time, 9%), defined as adults aged 18 to 24 enrolled and seeking a degree at a 4-year college or university and attending at least some in-person classes.1
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7373051-cpamm-survey-reveals-college-students-adhd-prescription-stimulant-abuse-misuse-and-diversion/
West Pharmaceutical Services, Inc. (NYSE: WST) and HealthPrize Technologies, LLC, today announced the completion of the first two phases of their four-phase strategic collaboration. The companies are working to integrate HealthPrize’s Software-as-a-Service (SaaS) medication adherence and patient-engagement platform with West’s injectable drug delivery systems to provide an end-to-end connected health solution for pharmaceutical companies and the patients they serve. The combined offering will provide voluntary, electronically connected drug delivery systems that track when patients take their medication. The HealthPrize system engages and educates patients to increase adherence and medical literacy, rewarding interaction and compliance with prescribed treatment plans, and contributing to better health outcomes.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7625851-west-pharma-healthprize-tech-collaboration/
More than 15 percent of reproductive-aged women have filled a prescription for an antidepressant medication during the years 2008–2013, according to a new analysis published today in the Centers for Disease Control and Prevention (CDC)’s Morbidity and Mortality Weekly Report (MMWR).
January is National Birth Defects Prevention Month and the CDC is working with the March of Dimes to raise awareness about the use of antidepressant medications by women of reproductive age, and what women should know and do for their own health and that of their babies. There is conflicting evidence about the potential link between some antidepressants and certain birth defects. Some commonly used antidepressants are sertraline (Zoloft), bupropion (Wellbutrin, Zyban), and citalopram (Celexa).
To view the multimedia release go to:
http://www.multivu.com/players/English/7709851-march-of-dimes-antidepressant-pregnancy-study/
Blink Health, America’s leading prescription drug savings platform, today launched a program to help #TreatType2 diabetes by committing to give away $10 million worth of medication to patients with type-2 diabetes. People living with diabetes who create an account on Blink Health’s website or free mobile app, starting today, will receive a free, one-year supply of the three most commonly prescribed generic medications for type-2 diabetes: metformin, glipizide and pioglitazone. The program will also cover these three medications for existing Blink Health patients who use them.
To view the multimedia release go to:
https://www.multivu.com/players/English/8117451-blink-health-type-2-diabetes-medications/
